FATE THERAPEUTICS INC - 8-K Filing
Fate Therapeutics updated its corporate presentation on June 4, 2026 for use at meetings and conferences including EULAR 2026. The update highlights progress in off-the-shelf cell therapy development with a focus on autoimmune diseases like lupus nephritis (LN) and cancer indications such as HER2-positive solid tumors. (Items: 8.01 Other Events On June 4, 2026, Fate Therapeutics, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $FATE